Abstract AIM: We report our experience with eribulin mesylate in a pancytopenic heavily pretreated patient with multiple bone metastases and bone marrow infiltration from breast cancer. METHODS: Eribulin mesylate was given at 1.4 mg/m(2) on day 1 and 8 every 3 weeks for a total of 11 courses. RESULTS: After seven cycles, evaluation with a bone marrow biopsy showed a large decrease of neoplastic involvement with substitution of osteolitic lesions for the osteoaddensant type. No unexpected acute toxicity was observed. CONCLUSION: To our knowledge, this represents the first report of bone marrow metastases from breast cancer treated with eribulin mesylate that obtained an improvement of hematopoietic values with an acceptable profile of tolerability and good compliance for the subject.
A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate / Pashaj, Etleva; Cortesi, L.; Proietto, Manuela; Bonacorsi, G.; Liardo, ELIANA VALENTINA; Federico, Massimo. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - ELETTRONICO. - 9:10(2013), pp. 1437-1442. [10.2217/fon.13.158]
A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate.
PASHAJ, Etleva;PROIETTO, Manuela;LIARDO, ELIANA VALENTINA;FEDERICO, Massimo
2013
Abstract
Abstract AIM: We report our experience with eribulin mesylate in a pancytopenic heavily pretreated patient with multiple bone metastases and bone marrow infiltration from breast cancer. METHODS: Eribulin mesylate was given at 1.4 mg/m(2) on day 1 and 8 every 3 weeks for a total of 11 courses. RESULTS: After seven cycles, evaluation with a bone marrow biopsy showed a large decrease of neoplastic involvement with substitution of osteolitic lesions for the osteoaddensant type. No unexpected acute toxicity was observed. CONCLUSION: To our knowledge, this represents the first report of bone marrow metastases from breast cancer treated with eribulin mesylate that obtained an improvement of hematopoietic values with an acceptable profile of tolerability and good compliance for the subject.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Pashaj E. et al.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
670.33 kB
Formato
Adobe PDF
|
670.33 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
